LX107 gene therapy for AIPL1-related retinal dystrophy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an early phase 1 interventional trial administering a subretinal injection of LX107 to one investigator-selected study eye in patients with genetically confirmed biallelic AIPL1 retinal dystrophy. Eligible participants are age 4 or older and must have a study eye with best-corrected visual acuity no better than 58 ETDRS letters at baseline. The protocol includes long-term follow-up visits to monitor safety, retinal structure, and visual function following treatment. The primary focus is safety with collection of preliminary efficacy signals in this rare, monogenic cause of retinal degeneration.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The subject and/or their guardian signs a written informed consent form and is willing to comply with the long-term follow-up protocol and supporting protocols.
2. Adult or pediatric patients (aged ≥ 4 years) diagnosed with AIPL1-IRD.
3. Definitive molecular diagnosis of biallelic AIPL1 gene mutations confirmed by next-generation sequencing combined with Sanger validation.
4. The study eye has a best-corrected visual acuity of no more than 58 letters (approximately equivalent to decimal visual acuity ≤ 0.3) using the ETDRS visual acuity chart at baseline.

Note: Only one eye will be designated as the "study eye" (i.e., the eye to receive treatment) at the investigator's discretion.

Exclusion Criteria:For any eye with the following conditions:

1. A history of ocular diseases that, in the investigator's judgment, may hinder the planned treatment or interfere with the interpretation of study endpoints (e.g., glaucoma, diabetic retinopathy, retinal vein occlusion, retinal detachment, posterior or panuveitis, etc.).
2. Any eye with a history of gene therapy for IRD or other hereditary neuro-ophthalmic diseases (including but not limited to other viral vector-based gene therapies, mRNA therapies, etc.).
3. A lack of sufficient viable retinal cells as determined by non-invasive methods such as OCT or ophthalmoscopy.
4. Any active intraocular or periocular infection in the study eye (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis).
5. A history of intraocular surgery (e.g., vitrectomy, cataract surgery, trabeculectomy, or other filtering surgery) in the 6 months prior to the screening visit.

   For any systemic conditions:
6. Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg. If the initial measurement exceeds the above limits, it may be repeated on the same day or another day during the screening period; if the subject is taking oral antihypertensive drugs, they must have been on a stable dose of the same drug for at least 30 days prior to screening.
7. Diabetic patients meeting any of the following criteria: ① known to have macrovascular complications; ② baseline HbA1c \> 7.5%; ③ receiving treatment with two or more oral hypoglycemic agents, insulin, or GLP-1 receptor agonists.
8. A history of any other diseases, metabolic disorders, physical examination findings, or clinical laboratory abnormalities that, in the investigator's judgment, may contraindicate the use of the study drug, interfere with the interpretation of study results, or place the subject at high risk of treatment complications, including but not limited to: AIDS, syphilis, acute/chronic active hepatitis B or C, coagulation disorders, a history of treated or untreated malignancy within the past 5 years (except for localized basal cell carcinoma of the skin or in situ cervical cancer), etc.
9. Any of the following laboratory abnormalities: ① platelet count \< 100 × 10⁹/L, hemoglobin (Hb) \< 10 g/dL (males) or \< 9 g/dL (females); ② aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 × ULN; ③ serum creatinine or urea \> 1.5 × ULN.
10. Administration of any other investigational drug (except vitamins and minerals) within 3 months prior to screening, or an attempt to participate in another clinical trial during the study period.
11. Other circumstances deemed unsuitable for enrollment by the investigator.
12. Unwillingness to use effective contraceptive methods during the study; pregnant or lactating women, or women planning to become pregnant or lactate during the study period.

Where it's running

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sonrotoclax plus azacitidine in high-risk MDS with increased blasts-2

  This study tests whether adding sonrotoclax to azacitidine can help people with newly diagnosed high-risk MDS with increased blasts-2 see better disease control and tolerable safety.

  Recruiting Phase 1/2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 5 other locations · NCT07885397

• Acupuncture to Improve Sleep and Reduce Pain After Lung Cancer Surgery (VATS)

  This trial tests whether acupuncture given around surgery can improve sleep and lessen chronic pain for adults undergoing video-assisted thoracoscopic lung cancer removal.

  Recruiting at 2 sites Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 1 other locations · NCT07662733

• STN-targeted non-invasive brain stimulation for Parkinson’s symptoms

  A non-invasive procedure called tTIS is tested in people with Parkinson’s to see if it helps motor and non-motor symptoms.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07625540

• Nimotuzumab plus Immunotherapy and Chemotherapy before surgery for locally advanced head and neck cancer

  This phase 2 trial tests whether adding nimotuzumab to immunotherapy and chemotherapy before surgery helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07601737

• Risk predictor for new urinary incontinence after prolapse surgery

  This study tests a model to predict which women might develop new stress urinary incontinence after pelvic organ prolapse repair.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07601282

• See if EUS-SWQ can accurately detect and grade liver fibrosis in adults with chronic liver disease

  This study tests whether the endoscopic ultrasound shear wave quantification (EUS-SWQ) can match liver biopsy results in adults with chronic liver disease to diagnose and stage fibrosis, and whether it offers safety and measurement advantages over FibroScan.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07588854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.